Rajasree Chakraborty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Rajasree Chakraborty has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Chandravanu Dash
Center for AIDS Health Disparities Research, Meharry Medical College, Nashville, Tennessee, USA
2 shared publications - Ananya Banerjee
The Ohio State University, Columbus, OH
1 shared publication - Annet Kirabo
Vanderbilt University Medical Center
1 shared publication - Antentor Hinton
Vanderbilt University
1 shared publication - Anupriya S
School of Biotechnology, KIIT University, Bhubaneswar, Odisha, India
1 shared publication - Azeez Aileru
Department of Foundational Sciences, East Carolina School of Dental Medicine, Greenville, NC 27834, USA
1 shared publication
Latest Publications
- Open Access
- 3 July 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (8) , 110440
The role of chromatin in retroviral preintegration complex function
- 3 July 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (8) , 110440
Open AccessThe role of chromatin in retroviral preintegration complex function
- 24 May 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 134 (11) , e150-e175
HIV-Associated Hypertension: Risks, Mechanisms, and Knowledge Gaps
HIV type 1 (HIV-1) is the causative agent of AIDS. Since the start of the epidemic, HIV/AIDS has been responsible for ≈40 million deaths. Additionally, an estimated 39 million people are currently infected with the virus. HIV-1 primarily infects immune cells, such as CD 4+ (cluster of differentiation 4 + ) T lymphocytes (T cells), and as a consequence, the number of CD 4+ T cells progressively declines in people living with HIV. Within a span of ≈10 years, HIV-1 infection leads to the systemic failure of the immune system and progression to AIDS. Fortunately, potent antiviral therapy effectively controls HIV-1 infection and prevents AIDS-related deaths. The efficacy of the current antiviral therapy regimens has transformed the outcome of HIV/AIDS from a death sentence to a chronic disease with a prolonged lifespan of people living with HIV. However, antiviral therapy is not curative, is challenged by virus resistance, can be toxic, and, most importantly, requires lifelong adherence. Furthermore, the improved lifespan has resulted in an increased incidence of non-AIDS–related morbidities in people living with HIV including cardiovascular diseases, renal disease, liver disease, bone disease, cancer, and neurological conditions. In this review, we summarize the current state of knowledge of the cardiovascular comorbidities associated with HIV-1 infection, with a particular focus on hypertension. We also discuss the potential mechanisms known to drive HIV-1–associated hypertension and the knowledge gaps in our understanding of this comorbid condition. Finally, we suggest several directions of future research to better understand the factors, pathways, and mechanisms underlying HIV-1–associated hypertension in the post-antiviral therapy era.
- 24 May 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 134 (11) , e150-e175
HIV-Associated Hypertension: Risks, Mechanisms, and Knowledge Gaps
HIV type 1 (HIV-1) is the causative agent of AIDS. Since the start of the epidemic, HIV/AIDS has been responsible for ≈40 million deaths. Additionally, an estimated 39 million people are currently infected with the virus. HIV-1 primarily infects immune cells, such as CD 4+ (cluster of differentiation 4 + ) T lymphocytes (T cells), and as a consequence, the number of CD 4+ T cells progressively declines in people living with HIV. Within a span of ≈10 years, HIV-1 infection leads to the systemic failure of the immune system and progression to AIDS. Fortunately, potent antiviral therapy effectively controls HIV-1 infection and prevents AIDS-related deaths. The efficacy of the current antiviral therapy regimens has transformed the outcome of HIV/AIDS from a death sentence to a chronic disease with a prolonged lifespan of people living with HIV. However, antiviral therapy is not curative, is challenged by virus resistance, can be toxic, and, most importantly, requires lifelong adherence. Furthermore, the improved lifespan has resulted in an increased incidence of non-AIDS–related morbidities in people living with HIV including cardiovascular diseases, renal disease, liver disease, bone disease, cancer, and neurological conditions. In this review, we summarize the current state of knowledge of the cardiovascular comorbidities associated with HIV-1 infection, with a particular focus on hypertension. We also discuss the potential mechanisms known to drive HIV-1–associated hypertension and the knowledge gaps in our understanding of this comorbid condition. Finally, we suggest several directions of future research to better understand the factors, pathways, and mechanisms underlying HIV-1–associated hypertension in the post-antiviral therapy era.
- 16 May 2022
- Published by Taylor & Francis in Nanomedicine
- Vol. 17 (11) , 753-764
Antiproliferative and Apoptotic Potential of Methotrexate Lipid Nanoparticles in A Murine Breast Cancer Model
Aim: To evaluate the efficacy of novel methotrexate-loaded nanoparticles (MTX-NPs) in vitro and in vivo in the treatment of breast cancer. Materials & methods: MTX-NPs were tested for cellular upta...
- 16 May 2022
- Published by Taylor & Francis in Nanomedicine
- Vol. 17 (11) , 753-764
Antiproliferative and Apoptotic Potential of Methotrexate Lipid Nanoparticles in A Murine Breast Cancer Model
Aim: To evaluate the efficacy of novel methotrexate-loaded nanoparticles (MTX-NPs) in vitro and in vivo in the treatment of breast cancer. Materials & methods: MTX-NPs were tested for cellular upta...